Indivior Pharmaceuticals announced a new $748.9 million contract with the U.S. Department of Veterans Affairs, a deal that will secure a steady supply‑chain partnership for the company’s opioid‑use‑disorder therapies across VA facilities nationwide.
The agreement covers drug supply and pharmaceutical preparation manufacturing services, ensuring that Indivior can deliver its long‑acting injectable treatments to federal health‑care providers on a recurring basis throughout the life of the contract.
The contract adds a predictable revenue stream that is expected to generate recurring sales, strengthening Indivior’s long‑term cash‑flow profile. For context, the company reported total net revenue of $1,239 million for fiscal year 2025 and $358 million in the fourth quarter of 2025; the VA contract represents a substantial portion of that revenue base and signals a significant new source of income.
By securing a major federal customer, Indivior positions itself as a key supplier to one of the nation’s largest health‑care systems. The deal validates the company’s manufacturing capabilities and supply‑chain reliability, and it opens the door to future government contracts that could further diversify its revenue streams.
Indivior’s flagship product, SUBLOCADE, generated $856 million in net revenue in fiscal year 2025, a 13% year‑over‑year increase. The VA contract is likely to boost SUBLOCADE demand within federal facilities, reinforcing the company’s market positioning in the opioid‑use‑disorder treatment space.
Management has emphasized accelerating SUBLOCADE growth and expanding adjusted EBITDA. CEO Joe Ciaffoni highlighted the company’s focus on Phase II of its Action Agenda, while CFO Ryan Preblick noted 2026 guidance of $1,125–$1,195 million in revenue and $535–$575 million in adjusted EBITDA, reflecting confidence in margin expansion and operational efficiency.
Market reaction was positive, with analysts noting the contract’s significance for Individer’s revenue pipeline and potential for future government contracts.
The VA agreement underscores Individer’s strategic shift toward stable, high‑margin government contracts, complementing its commercial growth and providing a diversified revenue base.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.